Short Squeeze Setup — velZ +0.67 · age 99w×0.45 · 13.17%
Founder-Led — founder/CEO led
Earnings Tailwind — ER in 24.234d · w1 med 1.4% (mag 1/3) · winRate 57.1% (rel 1/3) · n28
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: July 18, 2019
Headquarters: 989 East Hillsdale Boulevard, Foster City, CA, United States, 94404
Founder-Led: Yes — Christopher Peetz (Chief Executive Officer)
Key Metrics
Current Price
$122.13
Market Cap
$7.79B
Float
52.5M
Shares Outstanding
61.0M
P/E (Forward)
2,000.00
Price/Sales (TTM)
13.67
vs. Analyst Target
+20.0% to analyst PT
Profit Margin
-140.24%
Operating Margin (TTM)
-39.51%
Revenue (TTM)
$570M
Dividend Rate
None
Analyst Target Price
$146.50 (10 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$11.0M
-$103M
-$623,000
-$102M
2021
$19.1M
-$84.0M
$17.2M
-$65.4M
2022
$77.1M
-$136M
$64.7M
-$123M
2023
$186M
-$163M
$139M
-$136M
2024
$337M
-$87.9M
$255M
-$49.0M
2025
$521M
-$23.4M
$421M
$17.2M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$128M
-$5.9M
Sep 2025
$133M
$2.9M
Dec 2025
$149M
-$5.7M
Mar 2026
$160M
-$790M
Ownership & Float
Insider Ownership
1.4%
Institutional Ownership
114.4%
Short Float
13.2%
% of All Funds Holding
3.53%
Number of Funds Holding
290
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$108.09
Near-term / short-term trend
Weekly
40-Week SMA
$90.68
Medium-term trend
Weekly
80-Week SMA
$71.49
Cyclical trend (business cycle)
Weekly
200-Week SMA
$46.02
Secular trend (multi-year)
Monthly
10-Month SMA
$95.06
Near-term monthly trend
Monthly
20-Month SMA
$73.55
Medium-term monthly trend
Monthly
40-Month SMA
$52.35
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$100.00
support
1.27x
0 months ago
$80.00
support
1.33x
5 months ago
$52.00
support
1.91x
10 months ago
$45.00
support
1.03x
12 months ago
$34.50
support
1.25x
23 months ago
Historical Earnings Reactions (28 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
1.77%
0.89%
67.86%
9.02%
-2.96%
1 Day
2.90%
2.46%
67.86%
16.22%
-6.50%
1 Week
1.79%
1.37%
57.14%
21.43%
-19.88%
2 Weeks
4.00%
1.98%
60.71%
29.56%
-25.94%
1 Month
8.30%
6.28%
62.96%
45.51%
-25.42%
Next earnings: August 5, 2026 (24 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
6.6%
71.4%
7
Feb
3.8%
71.4%
7
Mar
-4.3%
42.9%
7
Apr
5.8%
57.1%
7
May
-2.5%
28.6%
7
Jun
10.6%
71.4%
7
Jul
7.6%
66.7%
6
Aug
10.8%
71.4%
7
Sep
-4.4%
28.6%
7
Oct
-10.8%
14.3%
7
Nov
8.5%
71.4%
7
Dec
31.5%
57.1%
7
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.38%
50.9%
328
Tuesday
0.03%
53.6%
362
Wednesday
0.04%
49.2%
358
Thursday
0.26%
50.4%
351
Friday
0.41%
52.6%
350
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 114.4%
Insider Transactions — Smart Summary
Total insider ownership: 1.4%
Founder-led management: Christopher Peetz (Chief Executive Officer)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Mirum Pharmaceuticals Inc
(MIRM) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.